Home › Trial NCT04828486
Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer
- Trial IDNCT04828486
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorMayo Clinic
- Enrollment14
- Start date2021-08-17
- ConditionsAdvanced Hepatocellular Carcinoma · BCLC Stage A Hepatocellular Carcinoma · BCLC Stage B Hepatocellular Carcinoma · BCLC Stage C Hepatocellular Carcinoma · Metastatic Hepatocellular Carcinoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.